US FDA submits user fee proposals to Congress
This article was originally published in SRA
Executive Summary
The fate of the US Food and Drug Administration's Prescription Drug User Fee Act programme and the first-ever user fee programmes for makers of generic drugs and biosimilars is now in the hands of Congress - with companies holding their collective breath that lawmakers will not tinker too much with the terms drug makers negotiated with regulators over much of past year1.